UNLABELLED: Corneal graft rejection can be prevented by local macrophage depletion, via subconjunctival injections with clodronate liposomes. To unravel the underlying immunological mechanism responsible for prolonged graft survival in this circumstance, the effect of this regimen on induction of donor-specific delayed type hypersensitivity (DTH) and anterior chamber associated immune deviation (ACAID) was determined. The study showed that although subconjunctival clodronate liposome-treatment failed to alter systemically induced DTH and ACAID, both types of immune response were absent in clodronate liposome-treated rats after corneal transplantation. Thus, elimination of macrophages from the corneal transplant site renders corneal allografts immunologically "invisible" to the recipient. PURPOSE: To determine whether local macrophage depletion, via administration of clodronate liposomes, alters delayed type hypersensitivity (DTH) responses and induction of anterior chamber associated immune deviation (ACAID) after corneal allotransplantation. METHODS: Clodronate liposome-treated and untreated rats received orthotopic corneal allografts and were tested for DTH responses and induction of ACAID towards donor antigens. Also in subconjunctivally treated and untreated rats, DTH responses were measured after subcutaneous immunization or induction of ACAID with allogeneic spleen cells. RESULTS: Subconjunctival injected clodronate liposomes prevented grafted rats from developing donor-specific DTH as well as ACAID. By contrast, subconjunctivally injected clodronate liposomes had no effect on donor-specific DTH responses after systemic immunization or on the induction of ACAID with allogeneic cells. CONCLUSIONS: Depletion of macrophages at the time of corneal allografting seems to render the grafts immunologically invisible to the recipients. This could explain why these grafts survive "indefinitely" without any other form of therapy.
UNLABELLED: Corneal graft rejection can be prevented by local macrophage depletion, via subconjunctival injections with clodronate liposomes. To unravel the underlying immunological mechanism responsible for prolonged graft survival in this circumstance, the effect of this regimen on induction of donor-specific delayed type hypersensitivity (DTH) and anterior chamber associated immune deviation (ACAID) was determined. The study showed that although subconjunctival clodronate liposome-treatment failed to alter systemically induced DTH and ACAID, both types of immune response were absent in clodronate liposome-treated rats after corneal transplantation. Thus, elimination of macrophages from the corneal transplant site renders corneal allografts immunologically "invisible" to the recipient. PURPOSE: To determine whether local macrophage depletion, via administration of clodronate liposomes, alters delayed type hypersensitivity (DTH) responses and induction of anterior chamber associated immune deviation (ACAID) after corneal allotransplantation. METHODS:Clodronate liposome-treated and untreated rats received orthotopic corneal allografts and were tested for DTH responses and induction of ACAID towards donor antigens. Also in subconjunctivally treated and untreated rats, DTH responses were measured after subcutaneous immunization or induction of ACAID with allogeneic spleen cells. RESULTS: Subconjunctival injected clodronate liposomes prevented grafted rats from developing donor-specific DTH as well as ACAID. By contrast, subconjunctivally injected clodronate liposomes had no effect on donor-specific DTH responses after systemic immunization or on the induction of ACAID with allogeneic cells. CONCLUSIONS: Depletion of macrophages at the time of corneal allografting seems to render the grafts immunologically invisible to the recipients. This could explain why these grafts survive "indefinitely" without any other form of therapy.
Authors: Delu Zhou; Ying-Ting Chen; Feeling Chen; Marianne Gallup; Trinka Vijmasi; Ahmad F Bahrami; Lisa B Noble; Nico van Rooijen; Nancy A McNamara Journal: Am J Pathol Date: 2012-07-04 Impact factor: 4.307
Authors: Lars Bellner; Giuseppina Marrazzo; Nico van Rooijen; Michael W Dunn; Nader G Abraham; Michal L Schwartzman Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191
Authors: T Oshima; K-H Sonoda; C Tsutsumi-Miyahara; H Qiao; T Hisatomi; S Nakao; S Hamano; K Egashira; I F Charo; T Ishibashi Journal: Br J Ophthalmol Date: 2006-02 Impact factor: 4.638
Authors: Tina Dietrich; Felix Bock; Don Yuen; Deniz Hos; Björn O Bachmann; Grit Zahn; Stanley Wiegand; Lu Chen; Claus Cursiefen Journal: J Immunol Date: 2009-12-16 Impact factor: 5.422
Authors: Tanja P A M Slegers; Gerard van der Veen; L Joep A Hermans; Lidy Broersma; Nico van Rooijen; Hendrika J Völker-Dieben; Gabriel van Rij; Ruth van der Gaag Journal: Graefes Arch Clin Exp Ophthalmol Date: 2003-04-16 Impact factor: 3.117